Aldeyra Therapeutics, Inc. (ALDX) — Stock Score Summary

Aldeyra Therapeutics, Inc. (ALDX) has a MoatMap StockRank of 4/100 based on Quality (26/100), Value (37/100), and Momentum (15/100) factor scores. The current signal is STRONG SELL. A clinical-stage biopharmaceutical company with binary regulatory risks and no structural cash flows, failing our quality criteria.

Aldeyra Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for immune-mediated diseases caused by inflammation and oxidative stress. It utilizes a proprietary RASP (reactive aldehyde species) modulator platform to target underlying disease mechanisms, with lead candidates in late-stage clinical trials for ocular and systemic inflammatory conditions. The company is a specialized biopharmaceutical firm focused on a distinct therapeutic approach, aiming to address significant unmet needs in inflammatory and autoimmune disorders.

Key Financial Metrics

Price$1.72
Market Cap$106M
P/E (Forward)-9.78
Price/Book2.52
Return on Equity-51.8%
Return on Invested Capital-72.2%
Debt/Equity36.80
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-20M

Aldeyra Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Aldeyra Therapeutics, Inc.’s (ALDX) StockRank?
MoatMap’s StockRank for Aldeyra Therapeutics, Inc. (ALDX) is 4/100, with a Strong Sell signal. It is a composite of Quality (26), Value (37), and Momentum (15) factor ranks across MoatMap’s 19,000+ stock universe.
Does Aldeyra Therapeutics, Inc. have an economic moat?
Aldeyra Therapeutics, Inc. (ALDX) has a Quality factor score of 26/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Aldeyra Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Aldeyra Therapeutics, Inc. (ALDX) is Strong Sell, based on a StockRank of 4/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Aldeyra Therapeutics, Inc. in?
Aldeyra Therapeutics, Inc. (ALDX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksALDX deep dive reportAI ChampionsHow we score stocksSense-check another stock